UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Operating revenue:
Personalized oncology solutions	$ 452	$ 623	$ 792	$ 1,245
Translational oncology solutions	1,430	1,760	3,001	4,158
Total operating revenue	1,882	2,383	3,793	5,403
Costs and operating expenses:
Cost of personalized oncology solutions	759	732	1,516	1,525
Cost of translational oncology solutions	960	698	1,924	1,576
Research and development	1,249	677	2,663	1,079
Sales and marketing	1,203	698	2,246	1,340
General and administrative	1,377	1,279	2,831	2,355
Total costs and operating expenses	5,548	4,084	11,180	7,875
Loss from operations	(3,666)	(1,701)	(7,387)	(2,472)
Other income (expense):
Change in fair value of warrant liability	625	(585)	780	(2,048)
Other (expense)	(27)	(29)	(62)	(30)
Total other income (expense)	598	(614)	718	(2,078)
Loss before provision for income taxes	(3,068)	(2,315)	(6,669)	(4,550)
Provision for income taxes	10	3	15	6
Net loss	$ (3,078)	$ (2,318)	$ (6,684)	$ (4,556)
Net loss per common share outstanding, including redeemable common stock, basic (in dollars per share)	$ (0.05)	$ (0.03)	$ (0.10)	$ (0.07)
Net loss per common share outstanding, including redeemable common stock, diluted (in dollars per share)	$ (0.05)	$ (0.03)	$ (0.11)	$ (0.07)
Weighted average common shares outstanding, including redeemable common stock, basic (in shares)	66,887,331	66,863,147	66,886,234	66,857,630
Weighted average common shares outstanding, including redeemable common stock, diluted (in shares)	67,855,325	66,863,147	67,854,228	66,857,630